The role of bisphosphonate in the treatment of bone metastases from prostate cancer

##plugins.themes.academic_pro.article.sidebar##

Published Jul 4, 2012
Download
pdf
Vol. 90 No. 7 (2012): Issue Jul 2012

##plugins.themes.academic_pro.article.main##

Sataa Sallami
Samir Ben Rhouma
Karim Cherif
Nawfel Benrais
Ali Horchani

Abstract

Bachground: Bone metastasis is very frequent in prostate cancer. It is a turning point that marks the severity of the disease. Before metastasis become symptomatic, treatment preventing bone events should be indicated.
Aim: To evaluate the role of bisphosphonate in the treatment of bone metastases from prostate cancer.
Methods: A review of literature
Results: Bisphosphonates play a very important role to prevent bone mass loss and to reduce bone complication events.
Conclusion: Bisphosphonates are recommended as preventive treatment at the time of diagnosis of bone metastatic prostate cancer.

Keywords:

Prostate cancer, bone metastasis, preventive treatment, bisphosphonate

##plugins.themes.academic_pro.article.details##

References

  1. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway MS, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA. 1991; 265:618-21.
  2. Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol. 2006; 49: 429-40.
  3. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157: 439-44.
  4. Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997; 79:545-50.
  5. Colombel M. Apport des bisphosphonates dans la prise en charge des métastases osseuses des cancers urologiques. Prog Urol. 2003;13:18-23.
  6. Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med. 2001;31:62-8.
  7. Kuban DA, Delbridge T, el-Mahdi AM, Schellhammer PF. Halfbody irradiation for treatment of widely metastatic carcinoma of the prostate. J Urol. 1989;141:572-4.
  8. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif. Tissue Int. 1991; 49: 407-15.
  9. Guise TA, Mundy GR. Cancer and bone. Endocrine Rev. 1998; 19:18-54.
  10. Green JR. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol. 2005; 44: 282-92.
  11. Lebret T, Méjean A. Physiopathologie, diagnostic et prise en charge des métastases osseuses du cancer de prostate. Prog Urol. 2008;18:S349-56.
  12. Clézardin P. Bisphosphonates et métastases osseuses des tumeurs solides: intérêt thérapeutique au-delà de l'activité anti-ostéolytique. Prog Urol. 2003; 13: 28-35.
  13. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today 2002; 38:91-102.
  14. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000; 289:1501-4.
  15. Zhang J, Dai J, Qi Y et al. Osteoprotegerin inhibits prostate cancerinduced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 2001;107:1235-44.
  16. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-93.
  17. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000; 88:2961-78.
  18. Santini D, Vincenzi B, Tonini G, Scarpa S, Baldi A. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003;9:3215.
  19. Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003;9: 295-306.
  20. Clézardin P, Gligorov J, Delmas P. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine. 2000;67: 22-9.
  21. Eaton CL, Coleman RE. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev. 2003; 29:189-98.
  22. Delmas PD. Bisphosphonates in the treatment of bone diseases. N Engl J Med. 1996; 1836-7.
  23. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997;57: 3890-4.
  24. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000; 60: 2949-54.
  25. Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 2002; 62:2708-14.
  26. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001;61:2602-8.
  27. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302:1055-61.
  28. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994; 9:745-51.
  29. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345: 948-55.
  30. Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst. 2007;99:765-76.
  31. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003;9: 2394-9.
  32. Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol. 2001;28:4-10.
  33. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000; 163:181-6.
  34. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998;16:3890-9.
  35. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer. 2008;113:1438-45.
  36. Berenson JR, Vescio RA, Rosen LS, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res. 2001;7:478-85.
  37. Colombel M. Prescription de bisphosphonates dans le cancer de prostate. Prog Urol. 2008;18:5-7.
  38. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;4:28-37.
  39. Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009;27:221-6.
  40. Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente JC. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. Am J Otolaryngol. 2009;30:390-5.
  41. Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol. 2006;24:4-12.
  42. Elomaa I, Kylmälä T, Tammela T, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol. 1992;24:159-66.
  43. Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002; 20:45-54.
  44. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol. 2001;165:136-40.
  45. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol. 2006;17:986-9.
  46. Dawson NA. Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease. Curr Opin Urol. 2002;12:413-28.
  47. Asahi H, Mizokami A, Maeda Y, Komatsu K, Koshida K, Namiki M. Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J Urol. 2003;169:281-2.
  48. Coleman R, Gnant M. New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care. 2009;3:213-8.
  49. Hong SJ, Cho KS, Cho HY, Ahn H, Kim CS, Chung BH. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer. Yonsei Med J. 2007;48:1001-8.
  50. Keller ET, Dai J, Escara-Wilke J, et al. New trends in the treatment of bone metastasis. J Cell Biochem. 2007;102:1095-102.
  51. Kikuno N, Urakami S, Nakamura S, Shiina H, Igawa M. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone. Int J Urol. 2007;14:82-4.
  52. Paule B, Cicco A. Les biphosphonates dans le traitement des métastases osseuses du cancer de la prostate Prog Urol. 2001;11:1205-12.
  53. Stewart AB, Lwaleed BA, Douglas DA, Birch BR. Current drug therapy for prostate cancer: an overview. Curr Med Chem Anticancer Agents. 2005;5:603-12.
  54. Rosenberg J, Small EJ. Prostate cancer update. Curr Opin Oncol. 2003;15:217-21.
  55. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006;107:530-5.
  56. Saad F, Higano CS, Sartor O, et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer. 2006; 4:257-62.
  57. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008; 19: 420-32.
  58. Karabulut B, Erten C, Gul MK, et al. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormonerefractory prostate cancer cells. Cell Biol Int. 2009; 33: 239-46.
  59. Efstathiou E, Bozas G, Kostakopoulos A, et al. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgenindependent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology. 2005;65:126-30.
  60. Di Lorenzo G, Autorino R, Perdonà S, et al. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol. 2007;52:1020-7.
  61. Budman DR, Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology. 2006;70:147-53.
  62. Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS. Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. Cancer Biother Radiopharm. 2009;24:543-50.
  63. Tu SM, Lin SH. Current trials using bone-targeting agents in prostate cancer. Cancer J. 2008;14:35-9.